MédiMabs antibodies

Click2Contact

MédiMabs provides research-grade monoclonal and polyclonal antibodies, both novel and known, for which defined affinity and purity specifications exist. It offers opportunities such as de novo antibody generation, peptide design and synthesis as well as antibody humanisation. It collaborates on R&D projects and acts as a distributor of existing antibody catalogues.

The company has introduced a new element to the commercialisation of research-grade antibodies. Through a supplemental royalty payment it secures the commitment of the provider to contribute to the technical support. It supports the medical research trend towards protein-based technology, providing scientists with the antibodies they require to detect and monitor proteins. Furthermore, it facilitates the elucidation of the expression and function of the multitude of novel proteins arising from the success of the human genome sequencing.

MédiMabs’ primary focus includes the fields of neuroscience, neurofilaments, cancer, kinases, cytoskeleton and inflammation.